Nvelop Therapeutics

iNclusion at Nvelop means fostering a caring environment where every Nveloper can flourish as their authentic self 365 days/year. This month, the team paused to recognize #Pride and celebrate the LGBTQIA+ community. 🧡🏳️🌈#PrideMonth

Our CSO, Melissa Bonner, will join fellow industry leaders at the upcoming Longwood Healthcare Leaders Spring MIT Conference for what is sure to be an exciting discussion focused on R&D collaboration and strategy. Learn more about the conference: https://ow.ly/8ZOW50SaNxJ #LongwoodHealthcareLeaders

While in Baltimore for #ASGCT2024 last week, the Nvelop team met with our recently appointed Scientific Advisory Board to provide updates on our continued progress and advances in delivery technology. We’re honored to collaborate with this group as we work to advance two potentially disruptive platforms for the delivery of genetic medicines to treat a wide range of diseases. Read more about our inaugural SAB here: https://ow.ly/KG7N50RH8ix

Great to have participated at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) meeting and share the first preclinical data from our novel DLVR-M delivery platform.   Thank you, Peter Cabeceiras, Ph.D., and Keith Joung, M.D., Ph.D., for leading our poster session and to everyone at ASGCT for a successful meeting! #ASGCT2024

Congratulations to our co-founder David R. Liu, Ph.D., on being named this year’s recipient of the Outstanding Achievement Award by the American Society of Gene & Cell Therapy. This is the organization's highest honor and tremendous recognition by David's peers for his contributions to the field and overall impact on human health.   For more information on the award, visit https://ow.ly/aVuV50RFFnI #ASGCT2024

#ASGCT2024 27th Annual Meeting Attendance ✈️ Today, at the American Society of Gene & Cell Therapy (ASGCT) annual conference, Nvelop Therapeutics will share the first preclinical data from our novel DLVR-M platform, created by gene editing pioneer Keith Joung, M.D., Ph.D. and his team at Massachusetts General Hospital. The platform is designed to deliver a broad array of cargoes that can include CRISPR, base editor and prime editor ribonucleoproteins, using engineered particles that have the potential to be fully humanized. See today's announcement here: https://ow.ly/2ZUi50RAeqV

We’re thrilled to announce that gene therapy veteran Luca Biasco, PhD has joined Nvelop as Vice President of Translational Research. Luca will lead the particle development team, advancing our novel delivery platforms as we work to unlock the potential of genetic medicines to treat a broad range of diseases. Read more: https://ow.ly/G0vh50RuGvi

We are pleased to introduce Nvelop’s Scientific Advisory Board, a distinguished group of leaders from the fields of gene therapy, gene editing, and drug delivery. It's a privilege to build upon their collective expertise and experience as we work to address the challenge of efficiently delivering therapeutic cargoes to target cells in vivo. Read more: https://ow.ly/G0vh50RuGvi

Our belief that great science is made possible through a caring company culture has remained steadfast since our inception in 2022. As our Nvelop team continues to grow and explore the unique capabilities of our in vivo delivery platforms, we’re working to foster an environment where our people thrive and are excited to share insight into Life at Nvelop. Follow us on Instagram: @lifeatnvelop https://ow.ly/tKtw50Rcfv9 View our open positions: https://ow.ly/6zs450RcfAI

We’re thrilled to introduce our CSO, Melissa Bonner, whose leadership in the development of genetic therapies, and commitment to improving the lives of patients will now drive Nvelop toward a new era of in vivo targeted medicines.   Read more: https://ow.ly/CBhs50Rbf0Q